Skip to main content

Table 5 Studies assessing effect of imatinib on glucose metabolism of subjects with T2DM

From: Effect of imatinib on plasma glucose concentration in subjects with chronic myeloid leukemia and gastrointestinal stromal tumor

Author

Year

N

Effect

Reference

Agostino et al.

2011

17

47% of the subjects could discontinue their medications. All the subjects had a reduction in FPG.

[2]

Breccia et al.

2004

7

85.7% of the subjects reduced FPG concentration allowing dose decrease of oral hypoglycemic agents.

[3]

Iurlo et al.a

2015

27

Improve FPG levels and reduction of the dosage of antihyperglycemic drugs.

[22]

Dingli et al. b

2007

7

There was no reduction of FG, HbA1c or antidiabetic treatment in any of the patients.

[9]

  1. FPG fasting plasma glucose
  2. aIn this study, the authors did not separate subjects with IFG and T2DM
  3. bTwo patients of the group with normal fasting glucose developed diabetes during the treatment with imatinib